These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 29439172)

  • 21. Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK Gene Rearrangements.
    Chang JC; Zhang L; Drilon AE; Chi P; Alaggio R; Borsu L; Benayed R; Travis WD; Ladanyi M; Antonescu CR
    J Thorac Oncol; 2019 May; 14(5):825-834. PubMed ID: 30550870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inflammatory myofibroblastic tumor with RANBP2 and ALK gene rearrangement: a report of two cases and literature review.
    Li J; Yin WH; Takeuchi K; Guan H; Huang YH; Chan JK
    Diagn Pathol; 2013 Sep; 8():147. PubMed ID: 24034896
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant crizotinib in advanced inflammatory myofibroblastic tumour with ALK gene rearrangement.
    Rafee S; Elamin YY; Joyce E; Toner M; Flavin R; McDermott R; Sheehy N; Hennessy B; O'Byrne K; Gleeson N; Osman N
    Tumori; 2015 Apr; 101(2):e35-9. PubMed ID: 25744866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ALK-negative lung inflammatory myofibroblastic tumor in a young adult: A case report and literature review of molecular alterations.
    Debonis SA; Bongiovanni A; Pieri F; Fausti V; De Vita A; Riva N; Gurrieri L; Vanni S; Diano D; Mercatali L; Ibrahim T
    Medicine (Baltimore); 2021 May; 100(20):e25972. PubMed ID: 34011083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors.
    Jiang J; Wu X; Tong X; Wei W; Chen A; Wang X; Shao YW; Huang J
    Lung Cancer; 2018 Jan; 115():5-11. PubMed ID: 29290262
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of ALK Immunohistochemistry for Optimal Therapeutic Strategy of Pulmonary Large-cell Neuroendocrine Carcinoma and Identification of a Novel
    Shimizu N; Akashi Y; Fujii T; Shiono H; Yane K; Kitahara T; Ohta Y; Kakudo K; Wakasa T
    Anticancer Res; 2019 Jan; 39(1):413-420. PubMed ID: 30591488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Case of Simultaneously Diagnosed Lung Adenocarcinoma and Endobronchial Inflammatory Myofibroblastic Tumor with Two Distinct Types of ALK Translocation.
    Zhao S; Liu W; Li S; Shi T; Chen Q; Li Q; Sun L; Ren D; Song Z; Huang C; Xu S
    Cancer Res Treat; 2021 Apr; 53(2):601-606. PubMed ID: 33091968
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inflammatory myofibroblastic tumor from molecular diagnostics to current treatment.
    Chmiel P; SłOWIKOWSKA A; Banaszek Ł; Szumera-CIEćKIEWICZ A; Szostakowski B; SPAłEK MJ; Świtaj T; Rutkowski P; Czarnecka AM
    Oncol Res; 2024; 32(7):1141-1162. PubMed ID: 38948020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inflammatory myofibroblastic tumor arising from soft tissues of extremities harboring a novel CLIP2-ALK fusion.
    Ding R; Li X; Zhu XM; Song QX; Fan QH; Zhang ZH; Gong QX
    Pathol Int; 2020 Oct; 70(10):798-803. PubMed ID: 32716129
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A case of inflammatory myofibroblastic tumor harboring EML4-ALK fusion with a brain metastasis responding to alectinib.
    Sakoda S; Tanaka K; Koga Y; Mikumo H; Tsuchiya-Kawano Y; Harada E; Tamiya S; Okamoto I
    Thorac Cancer; 2024 Feb; 15(5):415-418. PubMed ID: 38213097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Crizotinib in ALK
    Theilen TM; Soerensen J; Bochennek K; Becker M; Schwabe D; Rolle U; Klingebiel T; Lehrnbecher T
    Pediatr Blood Cancer; 2018 Apr; 65(4):. PubMed ID: 29286567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration.
    Pearson ADJ; Barry E; Mossé YP; Ligas F; Bird N; de Rojas T; Zimmerman ZF; Wilner K; Woessmann W; Weiner S; Weigel B; Venkatramani R; Valteau D; Trahair T; Smith M; Singh S; Selvaggi G; Scobie N; Schleiermacher G; Richardson N; Park J; Nysom K; Norga K; Merino M; McDonough J; Matloub Y; Marshall LV; Lowe E; Lesa G; Irwin M; Karres D; Gajjar A; Doz F; Fox E; DuBois SG; Donoghue M; Casanova M; Caron H; Buenger V; Bradford D; Blanc P; Barone A; Reaman G; Vassal G
    Eur J Cancer; 2021 Nov; 157():198-213. PubMed ID: 34536944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drastic initial response and subsequent response to two ALK inhibitors in a patient with a highly aggressive ALK-rearranged inflammatory myofibroblastic tumor arising in the pleural cavity.
    Ono A; Murakami H; Serizawa M; Wakuda K; Kenmotsu H; Naito T; Taira T; Koh Y; Ohde Y; Nakajima T; Endo M; Takahashi T
    Lung Cancer; 2016 Sep; 99():151-4. PubMed ID: 27565932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intraosseous inflammatory myofibroblastic tumor of the mandible with a novel ATIC-ALK fusion mutation: a case report.
    Tateishi Y; Okudela K; Kawai S; Suzuki T; Umeda S; Matsumura M; Kioi M; Ohashi K
    Diagn Pathol; 2016 Nov; 11(1):132. PubMed ID: 27846861
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ALK Is a Specific Diagnostic Marker for Inflammatory Myofibroblastic Tumor of the Uterus.
    Mohammad N; Haimes JD; Mishkin S; Kudlow BA; Leong MY; Chew SH; Koay E; Whitehouse A; Cope N; Ali RH; Köbel M; Stewart CJR; McCluggage WG; Lee CH
    Am J Surg Pathol; 2018 Oct; 42(10):1353-1359. PubMed ID: 30015720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
    Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
    Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathologic and Genomic Characterization of Inflammatory Myofibroblastic Tumors of the Head and Neck: Highlighting a Novel Fusion and Potential Diagnostic Pitfall.
    Kerr DA; Thompson LDR; Tafe LJ; Jo VY; Neyaz A; Divakar P; Paydarfar JA; Pastel DA; Shirai K; John I; Seethala RR; Salgado CM; Deshpande V; Bridge JA; Kashofer K; Brčić I; Linos K
    Am J Surg Pathol; 2021 Dec; 45(12):1707-1719. PubMed ID: 34001695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary inflammatory myofibroblastic tumour of the liver: a clinicopathological and genetic study including a subset with ETV6::NTRK3 fusion.
    Han Q; Zhang Z; He X; Chen M; Pang X; Chen C; Du T; Zhang H
    Histopathology; 2023 May; 82(6):925-936. PubMed ID: 36748182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement.
    Antonescu CR; Suurmeijer AJ; Zhang L; Sung YS; Jungbluth AA; Travis WD; Al-Ahmadie H; Fletcher CD; Alaggio R
    Am J Surg Pathol; 2015 Jul; 39(7):957-67. PubMed ID: 25723109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor.
    Ma Z; Hill DA; Collins MH; Morris SW; Sumegi J; Zhou M; Zuppan C; Bridge JA
    Genes Chromosomes Cancer; 2003 May; 37(1):98-105. PubMed ID: 12661011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.